Prophylactic Ivermectin in COVID-19 Contacts

Zagazig University340 enrolled

Overview

asymptomatic family close contact of confirmed COVID -19 patient will receive prophylactic ivermectin and will be followed up for 14 days for any symptoms \& diagnosis of COVID -19

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

NONE

Enrollment

340

Conditions

COVID

Interventions

Ivermectin TabletsDRUG

two doses 72 hours apart

Eligibility

Sex: ALLMin age: 16 YearsMax age: 70 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: family contact of confirmed COVID-19 case Exclusion Criteria: * refuse to participate and receive the drug pregnancy or lactation known hypersensitivity to ivermectin

Locations (1)

Zagazig University

Zagazig, Sharqia Province, Egypt

Outcomes

Primary Outcomes

Development of Symptoms ( Fever ,Cough, Sore Throat, Myalgia,Diarrhea, Shortness of Breath)

history taking and clinical examination

Time frame: within 14 days after enrollement

Secondary Outcomes

Development of COVID

by swab

Time frame: within 14 days after enrollement

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.